ArticleMolecular therapy. Advances2026
Overcoming lentiviral delivery limitations in hard-to-transduce suspension cells for genome-wide CRISPR screening.
Article in Molecular therapy. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- High-Content CRISPR Screening: Methods and Applications.MedComm · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lentiviral vectors are a widely used delivery modality, combining broad cell-type versatility and stable transgene integration into the host genome for long-term genetic manipulation. These properties make them indispensable tools for delivering molecular components in functional genomics and genome engineering applications. However, challenges such as unpredictable integration profiles and variable cell susceptibility to transduction may introduce experimental biases. Considering the impact of intrinsic cell line properties and transduction methodology, we optimized lentiviral delivery specifically in suspension-adapted Chinese hamster ovary (CHO)-K1 and human embryonic kidney (HEK)293-6E cells by systematically comparing two procedures: spinoculation and static transduction. We achieved significantly higher library delivery efficiencies by implementing a two-step static transduction protocol, while minimizing cellular stress, streamlining workflows, and eliminating scalability limitations encountered in large-scale applications like genome-wide CRISPR screening. To characterize the variation in lentiviral integration, we used droplet digital PCR (ddPCR) to quantify copy-number variation (CNV) both at the pooled-cell level and within individual clonal isolates. Our approach established a robust, enhanced lentiviral delivery strategy in difficult-to-transduce suspension cells and highlights the importance of modulating transduction rates to limit multiple integrations to ensure the consistency required for large-scale functional genomics applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.